|
|
|
|
|
23.02.26 - 16:57
|
XFRA: AUFHEBUNG VON AMTS WEGEN IN US00704R1095, CA57778R1001, US5949728530, CA83179X1087 (XETRA)
|
|
|
Folgende Geschaefte in der ISIN US00704R1095, Wertpapier-Name: ADLAI NORTYE LTD. SP.ADR, wurden von Amts wegen aufgehoben:
Folgende Geschaefte in der ISIN CA57778R1001, Wertpapier-Name: MAX POWER MINING, wurden von Amts wegen aufgehoben:
Folgende Geschaefte in der ISIN US5949728530, Wertpapier-Name: STRATEGY INC. PERP.STR.A, wurden von Amts wegen aufgehoben:
Folgende Geschaefte in der ISIN CA83179X1087, Wertpapier-Name: SMARTCENTRES REIT V.VTG, wurden von Amts wegen aufgehoben:
ISIN Datum Zeit Volumen Preis
US00704R1095 23.02.2026 10:40:32 40 8,75 EUR
CA57778R1001 23.02.2026 11:08:54 2.500 0,75 EUR
US5949728530 23.02.2026 12:27:16 2 88,50 EUR
CA83179X1087 23.02.2026 15:11:55 1 18,10 EUR...
|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 6 (XETRA)
|
|
|
SE0016797773
US5904794089
KYG8879R1048
GB00B0WJ3L68
US4385651033
US6067694041
US83600C3016
US5797801074
US60272J1034
KYG1821D1097
US6025663096
US5949728878
US5949728795
US5949728613
US5949728530
US60649T1079
KYG9891U1334
US74767N1072
CA57773Y2096
US14167R3084
US6067991041
MX01AM050019
BMG210A71016
AU000000GMG2
GB0033877555
US66980N2036
US00704R1095
JP3778270003
GRS524003001
CA6293521051
CA04017M2031
US74982T1034
CA23344V1085
CA6410701073
US6323471002
CA6261351077
US56624R1086
ID1000186505
CA86332K4000
GB00BNYM9W73
SE0017767031
AU0000253197
GB0006389398
IL0010826357
US60871R1005
SGXE27499115
JP3040880001
CA91016A1084
CA8919571023
US3903207039
IT0005568461
US43010T1043
KYG370481080
GB00BTWSXB68
CA7739151032
CA03967C2076
US87507T1016
AU0000453185
CA2924833023
AU0000226300
AU000000OFX5
CA68621J4019
US65447N1037
CNE100007CV2
SE0017833171
KYG8123S1066
US0389238769
BMG684371393
ID1000165004
SG1Q52922370
SE0015244884
CNE1000070L0
AU000000PAR5...
|
|
|
|
|
|
|
03.02.26 - 13:03
|
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing (GlobeNewswire EN)
|
|
|
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities purchase agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $140.0 million, before deducting placement agent fees and other expenses....
|
|
|
|
|
|
|
21.11.25 - 14:03
|
Adlai Nortye to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate in the following investor conferences:...
|
|
|
22.10.25 - 06:03
|
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire EN)
|
|
|
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA....
|
|
|
14.10.25 - 05:12
|
Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire EN)
|
|
|
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
